Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and immunogenicity of GlaxoSmithKline’s Ebola vaccine ChAd3-EBO-Z in children, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• ChAd3-EBO-Z

Snippet

Sponsor: GlaxoSmithKline | Conditions: Virus Diseases | Phase 2 | Status: COMPLETED | Results posted: 2018-05-03